Tudor Investment Corp ET AL lowered its stake in shares of FibroGen, Inc (NASDAQ:FGEN) by 35.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,296 shares of the biopharmaceutical company’s stock after selling 6,279 shares during the period. Tudor Investment Corp ET AL’s holdings in FibroGen were worth $278,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in FGEN. Ameritas Investment Partners Inc. purchased a new stake in shares of FibroGen during the first quarter valued at $111,000. Airain ltd bought a new stake in FibroGen during the first quarter worth approximately $236,000. Parametric Portfolio Associates LLC bought a new stake in FibroGen during the first quarter worth approximately $249,000. UBS Asset Management Americas Inc. bought a new stake in FibroGen during the first quarter worth approximately $288,000. Finally, Clinton Group Inc. bought a new stake in FibroGen during the first quarter worth approximately $297,000. 43.03% of the stock is owned by institutional investors.
FibroGen, Inc (NASDAQ:FGEN) remained flat at $41.00 on Friday. 1,348,330 shares of the company’s stock traded hands. FibroGen, Inc has a 12 month low of $15.60 and a 12 month high of $51.70. The stock’s market capitalization is $2.92 billion. The stock’s 50 day moving average is $36.29 and its 200 day moving average is $28.95.
COPYRIGHT VIOLATION NOTICE: “Tudor Investment Corp ET AL Sells 6,279 Shares of FibroGen, Inc (NASDAQ:FGEN)” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/08/19/tudor-investment-corp-et-al-has-278000-stake-in-fibrogen-inc-nasdaqfgen-updated-updated-updated.html.
A number of research firms have commented on FGEN. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a research report on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 target price for the company. in a research report on Friday, July 21st. BidaskClub downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Leerink Swann reaffirmed an “outperform” rating and issued a $82.00 target price (up previously from $52.00) on shares of FibroGen in a research report on Tuesday, August 8th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $75.00 price target on shares of FibroGen in a research note on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $60.17.
In other FibroGen news, VP Pat Cotroneo sold 95,000 shares of FibroGen stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $50.61, for a total transaction of $4,807,950.00. Following the completion of the sale, the vice president now directly owns 173,366 shares in the company, valued at $8,774,053.26. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Thomas B. Neff sold 38,636 shares of FibroGen stock in a transaction dated Wednesday, May 31st. The shares were sold at an average price of $26.21, for a total transaction of $1,012,649.56. Following the sale, the chief executive officer now owns 3,345,941 shares of the company’s stock, valued at $87,697,113.61. The disclosure for this sale can be found here. Insiders have sold 477,938 shares of company stock worth $17,570,645 over the last ninety days. 14.90% of the stock is owned by insiders.
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
What are top analysts saying about FibroGen Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for FibroGen Inc and related companies.